MaxCyte (NASDAQ:MXCT) Shares Up 0.7% - Time to Buy?

MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report)'s share price was up 0.7% during trading on Wednesday . The company traded as high as $1.54 and last traded at $1.51. Approximately 430,216 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 627,622 shares. The stock had previously closed at $1.50.Analysts Set New Price TargetsMaxCyte: Building the Future of Cell and Gene Therapy InnovationMXCT has been the subject of a number of research reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of MaxCyte in a report on Monday, December 29th. Wall Street Zen upgraded shares of MaxCyte from a "sell" rating to a "hold" rating in a research note on Saturday, November 22nd. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $7.00.Check Out Our Latest Research Report on MaxCyteMaxCyte Trading Up 0.7%The firm has a 50-day moving average of $1.58 and a 200 day moving average of $1.69. The stock has a market capitalization of $161.07 million, a price-to-earnings ratio of -3.43 and a beta of 1.22. MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. The firm had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. As a group, research analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current year. Hedge Funds Weigh In On MaxCyteA number of institutional investors have recently added to or reduced their stakes in MXCT. AQR Capital Management LLC grew its stake in shares of MaxCyte by 227.3% during the first quarter. AQR Capital Management LLC now owns 95,501 shares of the company's stock valued at $261,000 after acquiring an additional 66,323 shares in the last quarter. Mudita Advisors LLP boosted its holdings in MaxCyte by 3.3% in the first quarter. Mudita Advisors LLP now owns 3,328,441 shares of the company's stock valued at $9,087,000 after purchasing an additional 105,034 shares during the last quarter. Strs Ohio purchased a new position in MaxCyte in the first quarter valued at about $328,000. Farther Finance Advisors LLC grew its stake in MaxCyte by 7,935.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company's stock valued at $26,000 after purchasing an additional 11,665 shares in the last quarter. Finally, CWM LLC increased its holdings in MaxCyte by 92.7% during the 2nd quarter. CWM LLC now owns 12,132 shares of the company's stock worth $26,000 after purchasing an additional 5,836 shares during the last quarter. Institutional investors and hedge funds own 68.81% of the company's stock. MaxCyte Company Profile (Get Free Report)MaxCyte, Inc NASDAQ: MXCT is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company's instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.See AlsoFive stocks we like better than MaxCyteYou Still Think Silver’s a Joke? Watch What Happens Next.A U.S. “birthright” claim worth trillions - activated quietlyA month before the crashElon Taking SpaceX Public! $100 Pre-IPO Opportunity!YDES Could Be 2026's Biotech BreakthroughThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in MaxCyte Right Now?Before you consider MaxCyte, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here